Puromycin aminonucleoside (Synonyms: NSC 3056, PANS) |
Catalog No.GC10171 |
Une toxine de cellule épithéliale glomérulaire
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 58-60-6
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Cell experiment [1]: | |
Cell lines |
Madin-Darby canine kidney (MDCK) cells |
Preparation method |
The solubility of this compound in DMSO is >14.5mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37 ℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months. |
Reacting condition |
48 h |
Applications |
In vector- and PMAT-transfected MDCK cells, Puromycin aminonucleoside (PAN) exhibited cell cytotoxicity with the IC50 values of 48.9 ± 2.8 and 122.1 ± 14.5 μM, respectively. PAN (250 μM) was toxic to both PMAT-expressing and vector-transfected cells. Puromycin aminonucleoside uptake in PMAT-expressing cells was four fold higher at pH 6.6 than that at pH 7.4. |
Animal experiment [2,3]: | |
Animal models |
Nephrosis rats |
Dosage form |
Intravenous injection, 60 mg/kg, 150 mg/kg |
Application |
In nephrosis rats, the number of podocytes per glomerulus was 90.7 on Day 4 in PAN (8 mg/100 g, i.v.) treated group. The amount of nephrin per glomerulus in PAN-treated nephrosis rats reduced to 0.46 ± 0.06 fmol and 0.35±0.04 fmol on Day 4 and Day 7. The nephrin amount per podocyte was significantly decreased association with the development of proteinuria in Puromycin aminonucleoside nephrosis rats. Rats given PAN (100 mg/kg, s.c.) gained less weight and their serum creatinine levels were higher than the control rats, indicating Puromycin aminonucleoside impaired renal function. |
Other notes |
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
References: [1]. Xia L, Zhou M, Kalhorn T F, et al. Podocyte-specific expression of organic cation transporter PMAT: implication in puromycin aminonucleoside nephrotoxicity. American Journal of Physiology-Renal Physiology, 2009, 296(6): F1307-F1313. [2]. Kawakami, Hirotaka, et al. Dynamics of absolute amount of nephrin in a single podocyte in puromycin aminonucleoside nephrosis rats calculated by quantitative glomerular proteomics approach with selected reaction monitoring mode. Nephrology Dialysis Transplantation 27.4 (2011): 1324-1330. [3]. Nosaka, Kazuo, et al. An adenosine deaminase inhibitor prevents puromycin aminonucleoside nephrotoxicity. Free Radical Biology and Medicine 22.4 (1997): 597-605. |
IC50 : N/A
(IC50 est une mesure de la concentration d'un composé qui inhibe 50% de l'activité biologique d'une cible donnée. Dans ce contexte, "N/A" signifie que cette mesure n'est pas applicable ou n'a pas été déterminée.)Puromycine aminonucléoside, 3'-Amino-3'-désoxy-N6,N6-diméthyladénosine, est la partie aminonucléosidique de l'antibiotique puromycine. La néphrose induite par le puromycine aminonucléoside (PAN) chez les rats peut fournir un modèle pour étudier la pathogenèse des conditions protéinuriques sévères.
In vitro : Une étude précédente a utilisé la microscopie électronique à balayage (SEM) et à transmission (TEM) pour tester les effets in vitro de PAN sur les podocytes glomérulaires de rat. Des tranches de rein de rat ont été incubées avec PAN. L'analyse SEM des glomérules sur les tranches rénales a indiqué que l'incubation avec PAN diminuait le nombre de microvillosités sur les corps cellulaires des podocytes et augmentait le nombre de glomérules. La morphométrie TEM a montré que l'incubation avec PAN retardait significativement la perte des processus en pieds des podocytes observée dans les groupes témoins [1].
En français : In vivo : Chez les rats Wistar, de multiples injections de PAN ont entraîné une protéinurie sévère et soutenue ainsi que des lésions FSGHS de leurs glomérules. Chez les rats PVG/c, une dose plus élevée de PAN était nécessaire pour induire une protéinurie chronique. Dans la néphrose aiguë au PAN induite par une seule injection intraveineuse chez les rats Wistar, le mésangium présentait de grandes quantités de lipides contrairement à quelques petites gouttelettes lipidiques mésangiales dans les rats PVG/c atteints de néphrose. De plus, après l'injection de carbone colloïdal chez les rats PVG/c atteints d'une néphrose, aucune accumulation accrue n'a été trouvée dans le mésangium par rapport aux témoins non-protéinuriques [2].
Essai clinique : N/A
IC50 : N/A
(IC50 est une mesure de la concentration d'un composé qui inhibe 50% de l'activité biologique d'une cible spécifique. Dans ce contexte, "N/A" signifie que cette mesure n'est pas disponible.)References:
[1] Grond J,Muller EW,van Goor H,Weening JJ,Elema JD.? Differences in puromycin aminonucleoside nephrosis in two rat strains. Kidney Int.1988 Feb;33(2):524-9.
[2] Bertram JF,Messina A,Ryan GB.? In vitro effects of puromycin aminonucleoside on the ultrastructure of rat glomerular podocytes. Cell Tissue Res.1990 May;260(3):555-63.
Cas No. | 58-60-6 | SDF | |
Synonymes | NSC 3056, PANS | ||
Chemical Name | 4-amino-2-[6-(dimethylamino)purin-9-yl]-5-(hydroxymethyl)oxolan-3-ol | ||
Canonical SMILES | CN(C)C1=NC=NC2=C1N=CN2C3C(C(C(O3)CO)N)O | ||
Formula | C12H18N6O3 | M.Wt | 294.31 |
Solubility | ≥ 14.45 mg/mL in DMSO, ≥ 29.4 mg/mL in EtOH with gentle warming, ≥ 29.5 mg/mL in Water with gentle warming | Storage | Store at -20°C |
General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. |
Prepare stock solution | |||
1 mg | 5 mg | 10 mg | |
1 mM | 3.3978 mL | 16.9889 mL | 33.9778 mL |
5 mM | 0.6796 mL | 3.3978 mL | 6.7956 mL |
10 mM | 0.3398 mL | 1.6989 mL | 3.3978 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Average Rating: 5
(Based on Reviews and 30 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *